Celgene Corporation
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Celgene Corporation sits in the top decile of US sponsors by registered trial count (#434 of 15,742 sponsors by registered trial count).
Celgene Corporation: 40 sponsored US clinical trials, none currently recruiting.
Celgene Corporation sponsors 40 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 31 completed. 4 of these trials are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Small-cell Lung Cancer, with 1 trials.
Top-decile sponsor footprint
Celgene Corporation ranks in the top decile of sponsors by registered trial count (#434 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
31 of 40 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
40 total, page 1 of 1
Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
NCT02820935
Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study
NCT02321644
First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001
NCT02110420
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
NCT02034773
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT01744626
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
NCT00833833
Prevention of Restenosis Following Revascularization
NCT00518284
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT00474188
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
NCT00319969
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
NCT00179725
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
NCT00126893
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
NCT00179699
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
NCT00179660
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
NCT00179712
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
NCT00179751
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
NCT00179738
Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer
NCT00107094
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
NCT00179686
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
NCT00109772
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
NCT00910858
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
NCT00120120
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
NCT00073723
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
NCT00074646
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
NCT00072722
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
NCT00067743
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
NCT00064974
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
NCT00091624
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
NCT00057564
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
NCT00055562
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients
NCT00047476
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
NCT00040391
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
NCT00051116
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
NCT00446433
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
NCT00050843
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
NCT00046514
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
NCT00046527
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
NCT00046423
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
NCT00002157
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
NCT00002127
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 18 |
| Phase 3 | 4 |
Therapeutic Areas
How the Celgene Corporation early-phase archive is shaped
40 indexed studies, none listed as recruiting (0% open); 31 completed (78%).
Phase mix: 4 late (III/IV) vs 35 early (I/II) (early-phase heavy).
Top condition: Small-cell Lung Cancer (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Celgene Corporation: archived-pipeline peers nationwide
Peers matched on 40 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Celgene Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 40 archived trials
- Baptist Health South Florida · 40 trials · 43% recruiting
- BTL Industries · 40 trials · 8% recruiting
- Harvard School of Public Health (HSPH) · 40 trials · 3% recruiting
- Intuitive Surgical · 40 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Celgene Corporation page
40 registered trials is a research-attention snapshot, not an endorsement of Celgene Corporation or any single study.
- None of Celgene Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Small-cell Lung Cancer is the condition Celgene Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Small-cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Celgene Corporation pipeline card: 40 registered trials from official public datasets.Report a data error.